---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-025835"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:26:56.132942+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%

## Summary
- Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.
- Full year pro forma net sales $292.7M, up 8.1%; adjusted EBITDA positive at $7.6M.
- Cash balance $55.9M; entered $25M revolving credit facility with J.P. Morgan.
- Received CPT Category I code for NanoKnife IRE for pancreatic lesions, effective Jan 2027.
- FY2026 guidance: net sales $305-310M; pro forma adjusted EBITDA $3-8M.

## SEC filing metadata
- accession: 0001140361-25-025835
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036125025835/0001140361-25-025835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036125025835/ef20051984_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-025835
- JSON: https://secwatch.observer/filing/0001140361-25-025835.json
- Plain text: https://secwatch.observer/filing/0001140361-25-025835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.